Product image of Intratect (Human Normal Immunoglobulin) supplied by GNH India

Intratect

Active Ingredient:
Human Normal Immunoglobulin
Origin:
EU

Intratect (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Intratect, is an immunoglobulin presented as a solution for injection for intravenous use. It provides passive immunity and is indicated for primary and secondary immunodeficiency diseases, Kawasaki disease, and immune thrombocytopenic purpura, helping to reduce infections and modulate immune responses in affected patients.

GNH India supplies Intratect as a licensed, GDP‑compliant international pharmaceutical supplier originating from the European Union market and serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide across multiple continents.

Manufacturer / TM Owner

Biotest Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Intratect is used in immune‑mediated conditions to replace deficient antibodies and modulate immune activity.
  • Primary immunodeficiency diseases: restores IgG levels to reduce infection frequency.
  • Secondary immunodeficiency (e.g., chemotherapy, HIV): provides passive immunity to support immune function during treatment.
  • Kawasaki disease: reduces inflammation and lowers risk of coronary artery complications.
  • Immune thrombocytopenic purpura (ITP): increases platelet counts by modulating autoimmune destruction.
  • Idiopathic thrombocytopenic purpura: helps raise platelet levels through immune regulation.

How It Works

  • Human Normal Immunoglobulin consists of pooled IgG antibodies derived from healthy donors. After intravenous infusion, the IgG distributes throughout the vascular and extravascular compartments, where it binds to pathogens, toxins and immune complexes, neutralizing them. The antibodies also interact with Fc receptors on immune cells, modulating complement activation and cytokine release, thereby dampening excessive immune responses and providing passive protection against infections.

Side Effects

Intratect may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Headache
  • Fever
  • Chills
  • Nausea
  • Fatigue
  • Infusion‑related reactions (e.g., flushing, erythema)

Serious or Rare Side Effects

  • Anaphylaxis or severe allergic reactions
  • Thromboembolic events (e.g., deep vein thrombosis)
  • Acute renal dysfunction
  • Aseptic meningitis
  • Hemolysis
  • Severe thrombocytopenia

Precautions & Warnings

  • Before initiating Intratect therapy, clinicians should consider several safety precautions to minimize risks.
  • Assess IgG levels: determine baseline immunoglobulin concentrations to guide dosing.
  • Monitor for infections: watch for new or worsening infections during treatment.
  • Screen for allergic history: identify prior reactions to blood products or immunoglobulins.
  • Adjust infusion rate: reduce speed if infusion‑related reactions occur.
  • Avoid concurrent blood products: unless clinically necessary, to prevent overload.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Intratect can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid)

  • Live attenuated vaccines: may be neutralized, reducing vaccine effectiveness.
  • High‑dose aspirin or other NSAIDs: increased risk of bleeding complications.
  • Concurrent immunoglobulin products: risk of volume overload and duplicate therapy.
  • Rituximab or other B‑cell depleting agents: may diminish Intratect efficacy.
  • Anticoagulants (e.g., warfarin): potential for enhanced anticoagulant effect.

Moderate Interactions (Monitor Closely)

  • Diuretics: may increase risk of renal stress during infusion.
  • ACE inhibitors: possible hypotension during rapid infusion.
  • Corticosteroids: may mask signs of infection.
  • Antibiotics with nephrotoxic potential: monitor renal function.

Frequently Asked Questions

Intratect is an intravenous immunoglobulin (IVIG) preparation indicated for patients with primary or secondary immunodeficiency disorders, Kawasaki disease, and immune thrombocytopenic purpura. It supplies pooled IgG antibodies to replace deficient immune proteins, reduce infection risk, and modulate abnormal immune activity in these conditions.

Human Normal Immunoglobulin provides passive immunity by delivering a broad spectrum of IgG antibodies collected from healthy donors. These antibodies bind to pathogens, toxins, and immune complexes, neutralizing them, while also interacting with immune cell receptors to regulate complement activation and cytokine release, thereby tempering excessive immune responses.

The dose of Intratect is individualized by the prescribing clinician based on factors such as the patient’s body weight, baseline IgG level, severity of the immunodeficiency, and the specific indication being treated. Dosing regimens are established in accordance with clinical guidelines and the patient’s therapeutic response.

Safety data for Intratect in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Clinicians must weigh the potential benefits to the mother against any possible risks to the fetus or infant, and use the medication only if clearly indicated.

To order Intratect, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Intratect is comparable to other IVIG preparations in that it contains pooled IgG antibodies and is administered intravenously. Differences may lie in manufacturing processes, stabilizers, and regulatory approvals. Clinicians may choose a product based on factors such as tolerability, infusion rate, and specific regulatory status in their region.

Intratect must be stored at 2‑8 °C (refrigerated). It should be kept in its original container, protected from light, and must never be frozen or shaken. Maintaining the cold chain is essential to preserve product stability and efficacy.

Intratect is administered as an intravenous infusion by a qualified healthcare professional. The infusion rate is usually started slowly and may be increased as tolerated. Monitoring for infusion‑related reactions is recommended throughout the administration period.

Serious adverse events linked to Intratect include anaphylaxis, thromboembolic complications, acute renal dysfunction, aseptic meningitis, hemolysis, and severe thrombocytopenia. Prompt recognition and management of these reactions are critical, and patients should be observed closely during and after infusion.

Intratect is contraindicated in patients with a known severe hypersensitivity to immunoglobulin products or any of its excipients. Caution is also advised for individuals with uncontrolled hypercoagulable states, severe renal impairment, or those who have experienced serious adverse reactions to previous IVIG therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Normal Immunoglobulin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT